Literature DB >> 12175666

Coronary angioplasty versus medical therapy for angina. Health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial.

M Sculpher1, D Smith, T Clayton, R Henderson, M Buxton, S Pocock, D Chamberlain.   

Abstract

AIMS: The second Randomized Intervention Treatment of Angina (RITA-2) trial compares an initial strategy of PTCA with continued medical management in patients with arteriographically proven coronary artery disease. This paper employs resource use data collected in the trial to compare the health service costs of the two strategies over 3 years follow-up. METHODS AND
RESULTS: 1018 patients were randomized, 504 to PTCA and 514 to continued medical management. Health service resource use data were collected prospectively on all patients. Hospital unit costs were estimated in collaboration with five U.K. centres. PTCA patients underwent more subsequent coronary arteriograms, but subsequent (non-randomized) PTCAs were more common in patients randomized to medical management (118 procedures in 102 patients) compared to those randomized to PTCA (73 procedures in 62 patients). The likelihood of undergoing CABG was similar in the two groups. The use of antianginal medications was higher in patients randomized to an initial strategy of medical management. There was an overall mean additional cost per patient over 3 years in patients randomized to PTCA of pound 2685 (95% CI pound 2074- pound 3322).
CONCLUSIONS: In RITA-2, the cost of an initial strategy of PTCA exceeded the cost of an initial strategy of medical management by 74% over 3 years. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175666     DOI: 10.1053/euhj.2001.3075

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

Review 1.  Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis.

Authors:  Yolanda Bravo Vergel; Stephen Palmer; Christian Asseburg; Elisabeth Fenwick; Mark de Belder; Keith Abrams; Mark Sculpher
Journal:  Heart       Date:  2007-08-23       Impact factor: 5.994

2.  Financial ties that might bind: Consider palliative coronary intervention.

Authors:  Michael R Chester
Journal:  BMJ       Date:  2008-01-12

3.  Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials.

Authors:  Jacqueline B Shreibati; JoAnn E Manson; Karen L Margolis; Rowan T Chlebowski; Marcia L Stefanick; Mark A Hlatky
Journal:  Am Heart J       Date:  2017-12-27       Impact factor: 4.749

4.  Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting.

Authors:  Judy Kempf; Erin Buysman; Diana Brixner
Journal:  Am Health Drug Benefits       Date:  2011-09

5.  Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Mark A Hlatky; Derek B Boothroyd; Kathryn A Melsop; Laurence Kennedy; Charanjit Rihal; William J Rogers; Lakshmi Venkitachalam; Maria M Brooks
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

6.  What do patients really want? Patients' preferences for treatment for angina.

Authors:  Ann Bowling; Lucy Culliford; David Smith; Gene Rowe; Barnaby C Reeves
Journal:  Health Expect       Date:  2008-06       Impact factor: 3.377

7.  Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial.

Authors:  Mark Sculpher; Andrea Manca; Jason Abbott; Jayne Fountain; Su Mason; Ray Garry
Journal:  BMJ       Date:  2004-01-07

8.  Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study.

Authors:  S C Griffin; J A Barber; A Manca; M J Sculpher; S G Thompson; M J Buxton; H Hemingway
Journal:  BMJ       Date:  2007-03-05

9.  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?

Authors:  Vasilios G Athyros; Thomas D Gossios; Konstantinos Tziomalos; Matilda Florentin; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

10.  Economic evaluation of increasing population rates of cardiac catheterization.

Authors:  Fiona M Clement; William A Ghali; Stephane Rinfret; Braden J Manns
Journal:  BMC Health Serv Res       Date:  2011-11-24       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.